Clinical trial NCT02080455: Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.
Official title: A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Atorvastatin, a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Effect of Atorvastatin on the Pharmacokinetics of Lomitapide
Lead sponsor: Aegerion Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2014-03-06
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The primary objective of this study is to assess the effect of atorvastatin, a weak cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and its 2 primary metabolites, M1 and M3.

Detailed description: This study will be a single center, randomized, open-label, 2-arm study to evaluate the effects of atorvastatin, a weak CYP3A4 inhibitor, on the PK of lomitapide in healthy male and female subjects when atorvastatin is administered simultaneously with lomitapide and when it is administered 12 hours after lomitapide.

Eligibility criteria: Inclusion Criteria:

1. Healthy males and females, between 18 and 55 years of age inclusive
2. BMI between 18.5 and 32.0 kg/m2, inclusive; total body weight of \>110 lbs (50 kg);
3. in good health, determined by no clinically significant or relevant abnormalities identified by a detailed medical history and medical exam
4. creatine phosphokinase, AST, and ALT levels must be below 1.5 times the upper limit of normal
5. clinical laboratory evaluations within the reference range for the test laboratory
6. negative test for selected drugs of abuse
7. negative hepatitis panel and negative HIV antibody screens
8. males will either be sterile or agree to use approved methods of contraception
9. all females must have a negative serum beta human chorionic gonadotropin pregnancy test and will be required to use a medically acceptable method of contraception.
10. able to comprehend and willing to sign an Informed Consent Form

Exclusion Criteria:

1. significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI, neurological, or psychiatric disorder
2. history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
3. history of stomach or intestinal surgery or resection
4. history of Gilbert's Syndrome or suspicion of Gilbert's Syndrome
5. subjects who have an abnormality in the 12-lead ECG
6. use of any drugs of abuse for 6 months prior to Check-in;
7. subjects who consume more than 14 units of alcohol per week or who have a significant history of alcoholism or drug/chemical abuse within 1 year prior to Check-in
8. use of any tobacco- or nicotine-containing products within 6 months prior to Check-in;
9. participation in any other investigational study drug trial within 30 days prior to Check-in;
10. use of any prescription medications/products within 14 days prior to Check-in unless deemed acceptable by the Investigator and Sponsor
11. use of any over-the-counter, nonprescription preparations within 7 days prior to Check-in, unless deemed acceptable by the Investigator and Sponsor
12. use of alcohol-, grapefruit- (including star fruit), or caffeine-containing foods or beverages within 72 hours prior to Check-in and through Study Completion
13. poor peripheral venous access;
14. donation of blood (500 mL) from 30 days prior to Screening through Study Completion
15. receipt of blood products within 2 months prior to Check-in;
16. any acute or chronic condition, scheduled hospitalization (inclusive of elective surgery during study) or scheduled travel prior to completion of all study procedures which, in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in this clinical study;
17. subjects who, in the opinion of the Investigator, should not participate in this study.

Primary outcomes:
measure: Cmax
timeFrame: Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing
measure: Tmax
timeFrame: Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing
measure: AUC0-t
timeFrame: Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing
measure: AUC0-∞
timeFrame: Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing
measure: t1/2
timeFrame: Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing
Secondary outcomes:
measure: Cmax
timeFrame: Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing
measure: Tmax
timeFrame: Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing
measure: AUC0-t
timeFrame: Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing
measure: AUC0-∞
timeFrame: Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing
measure: t1/2
timeFrame: Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Covance Clinical Research Unit, Inc
state: Texas
Study officials:
affiliation: Cheif Medical Officer
name: Mark Sumeray, MD
role: STUDY_CHAIR
affiliation: Covance
name: T. Alex King, MD, CPI
role: PRINCIPAL_INVESTIGATOR
References: